Yassin, M.T., Mostafa, A.A., Al-Askar, A.A. and Bdeer, R. (2020) In Vitro Antifungal Resistance Profile of Candida Strains Isolated from Saudi Women Suffering from Vulvovaginitis. European Journal of Medical Research, 25, Article No. 1.
https://doi.org/10.1186/s40001-019-0399-0

has been cited by the following article:

• TITLE: A Clinical Study to Assess the Effectiveness of Oral Combination Kit Therapy in Syndromic Management of Abnormal Vaginal Discharge (FEMINE Study) in Kinshasa, Democratic Republic of Congo

  AUTHORS: Feruzi Michel Mangala, Muela Andy Mbangama, Di-Mosi-Nkoy Roger Wumba, Ambis Joëlle Lumaya, Nkongolo Freddy Muamba, Tshitadi Jean Mukendi, Ndombasi Neilda Lemba, Otem Christian Ndesanzim, Nkashama Bienvenu Kazadi, Banza Jesual Lotoy, Umba Adrien Tandu, Mushengezi Dieudonné Sengeyi, Mwimba Roger Mbungu

  KEYWORDS: Oral Combination Kit Therapy, Syndromic Management, Abnormal Vaginal Discharge

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.14 No.1, January 31, 2024

  ABSTRACT: Background: Vaginal discharge is one of most common and nagging problems that women face. About 20% - 25% of women who visit gynecology department complain of vaginal discharge and leucorrhoea. An orally administered combination kit, containing 2 g secnidazole, 1 g azithromycin and 150 mg fluconazole (Azimyn FS Kit), has been successfully evaluated in clinical trials and used in several countries for management syndromic vaginal discharge due to infections. Methods: This is a longitudinal study which aimed to verify the clinical efficacy of the combined oral kit containing secnidazole, azithromycin and fluconazole (Azimyn FS Kit®) in the syndromic treatment of abnormal vaginal discharge in patients received in outpatient consultations in Kinshasa/DR Congo from March to September 2023. Results: Majority of patients had whitish vaginal discharge (51.6%) of average abundance (56.2%), accompanied by pruritus in 72.1% of cases, and dyspareunia in 23.5% of cases and hypogastralgia in 40.2% of cases. One week after treatment with the Azimyn FS® combined kit, at the greatest majority of patients (97.3%), abnormal vaginal discharge had decreased by more than 50% (84.1%). Two weeks after treatment with the Azimyn FS® combined kit, almost all patients (97.3%) no longer had abnormal vaginal discharge which had completely disappeared. Conclusion: A single dose of secnidazole, azithromycin and fluconazole in the form of an oral combi-kit (Azimyn FS Kit) has shown excellent therapeutic effectiveness in the syndromic treatment of abnormal vaginal discharge wherein patients were treated without diagnostic confirmation.